Dexmedetomidine Cuts Incidence of Postpartum Depression After C-Section
26 Jan 2024
Clinical ResultPhase 3Clinical Study
FRIDAY, Jan. 26, 2024 -- For women with prenatal depression undergoing cesarean delivery, dexmedetomidine reduces the incidence of positive postpartum depression (PPD) screening, according to a study published online Jan. 25 in JAMA Network Open.
Yingyong Zhou, Ph.D., from The Third Xiangya Hospital of Central South University in Changsha, China, and colleagues conducted a randomized clinical trial involving 338 women who screened positive for prenatal depression and were scheduled for elective cesarean delivery at two hospitals to assess the efficacy and safety of dexmedetomidine for prevention of PPD. A total of 338 participants were randomly assigned in a 1:1 ratio to receive dexmedetomidine or saline, infused for 10 minutes after delivery. After infusion, sufentanil or dexmedetomidine plus sufentanil was administered for 48 hours in the control and dexmedetomidine groups, respectively.
The researchers found that the incidence of positive PPD screening at seven and 42 days postpartum was significantly reduced in the dexmedetomidine group versus the control group (day 7: 12.6 versus 32.1 percent; risk ratio, 0.39; day 42: 11.4 versus 30.3 percent; risk ratio, 0.38). No significant difference was seen between the groups in terms of adverse events, but an increased incidence of hypotension was seen in the dexmedetomidine group (18.3 versus 9.5 percent; risk ratio, 2.15).
"Preventive administration of dexmedetomidine in the early postpartum period reduced the incidence of positive PPD screening, reduced postoperative pain, improved sleep quality, and maintained a favorable safety profile," the authors write. "Its antidepressant effect may be related to brain-derived neurotrophic factor upregulation and/or downregulation of pro-brain-derived neurotrophic factor."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.